Blood cancer patients on Bruton’s tyrosine kinase inhibitors should continue at time of COVID-19 vaccination, study says

by

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study suggests.

Leave A Comment

Your email address will not be published. Required fields are marked *